Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016

Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016
Published Oct 26, 2016
73 pages — Published Oct 26, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia Associated With Alzheimer's Disease Pipeline Review, H2 2016, provides an overview of the Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline landscape.

Dementia is a general term for loss of memory and other mental abilities severe enough to interfere with daily life. Alzheimer's is a type of dementia. Symptoms include depression, social withdrawal, mood swings, irritability and aggressiveness and loss of inhibitions. Risk factors include age, family history and mild cognitive impairment. Treatment includes cholinesterase inhibitors and healthy life style.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia Associated With Alzheimer's Disease Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dementia Associated With Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia Associated With Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Unknown stages are 6, 2 and 1 respectively for Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively for Dementia Associated With Alzheimer's Disease.

Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia Associated With Alzheimer's Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Dementia Associated With Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dementia Associated With Alzheimer's Disease (Central Nervous System) therapeutics and enlis

  
Source:
Document ID
GMDHC8589IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Dementia Associated With Alzheimer's Disease Overview71
Therapeutics Development82
  Pipeline Products for Dementia Associated With Alzheimer's Disease Overview81
  Pipeline Products for Dementia Associated With Alzheimer's Disease Comparative Analysis91
Dementia Associated With Alzheimer's Disease Therapeutics under Development by Companies101
Dementia Associated With Alzheimer's Disease Therapeutics under Investigation by Universities/Institutes111
Dementia Associated With Alzheimer's Disease Pipeline Products Glance123
  Clinical Stage Products121
  Early Stage Products131
  Unknown Stage Products141
Dementia Associated With Alzheimer's Disease Products under Development by Companies151
Dementia Associated With Alzheimer's Disease Products under Investigation by Universities/Institutes161
Dementia Associated With Alzheimer's Disease Companies Involved in Therapeutics Development178
  Adamas Pharmaceuticals, Inc.171
  AgeneBio Inc.181
  Amarantus Bioscience Holdings, Inc.191
  Boehringer Ingelheim GmbH201
  Chase Pharmaceuticals Corporation211
  Eisai Co., Ltd.221
  H. Lundbeck A/S231
  MediPost Co., Ltd.241
Dementia Associated With Alzheimer's Disease Therapeutics Assessment2510
  Assessment by Monotherapy Products251
  Assessment by Combination Products261
  Assessment by Target272
  Assessment by Mechanism of Action292
  Assessment by Route of Administration312
  Assessment by Molecule Type332
Drug Profiles3524
  (donepezil hydrochloride + memantine hydrochloride ER) Drug Profile352
  (donepezil hydrochloride + solifenacin succinate) Drug Profile372
  BI-409306 Drug Profile392
  E-2609 Drug Profile413
  eltoprazine Drug Profile445
  Gln-1062 Drug Profile493
  levetiracetam Drug Profile522
  LUAF-20513 Drug Profile541
  Neurostem Drug Profile552
  salicylamine Drug Profile571
  TAK-070 Drug Profile581
Dementia Associated With Alzheimer's Disease Dormant Projects591
Dementia Associated With Alzheimer's Disease Discontinued Products601
Dementia Associated With Alzheimer's Disease Product Development Milestones6111
  Featured News &Press Releases611
    Aug 31, 2016: Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC Patent Litigation611
    Jul 27, 2016: Chase Pharmaceuticals Presents Phase 2 Results for CPC-201 at 2016 Alzheimer s Association International Conference612
    Feb 17, 2016: AgeneBio to Present at Neuroscience BioPartnering &Investment Forum631
    Dec 15, 2015: AgeneBio Launches New HOPE4MCI Phase 3 Clinical Trial Website631
    Dec 08, 2015: Amarantus Announces Positive Phase 2 Data for Eltoprazine in Alzheimer's Aggression642
    Nov 24, 2015: AgeneBio to Present at Future of Innovation in Medicine Conference661
    Oct 22, 2015: AgeneBio to Present at 8th Annual Clinical Trials on Alzheimer s Disease671
    Sep 15, 2015: NIH Awards $7.5 Million Grant for AgeneBio HOPE4MCI Phase 3 Clinical Trial to Delay the Onset of Alzheimer's Dementia671
    Mar 11, 2015: AgeneBio Announces Publication of Phase 2 Clinical Trial Results for New Approach to Delaying the Onset of Alzheimer s Dementia681
    Jan 28, 2015: AgeneBio Receives Grant from Alzheimer s Drug Discovery Foundation for New Approach to Delaying the Onset of Alzheimer s Dementia691
    May 20, 2014: Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories701
    May 15, 2012: Adamas Announces Successful End-Of-Phase II Meeting With FDA For Arimenda702
Appendix722
  Methodology721
  Coverage721
  Secondary Research721
  Primary Research721
  Expert Panel Validation721
  Contact Us721
  Disclaimer731

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016" Oct 26, 2016. Alacra Store. May 04, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Dementia-Associated-With-Alzheimer-s-Disease-Pipeline-Review-H2-2016-2088-16704>
  
APA:
Global Markets Direct - Market Research. (2016). Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016 Oct 26, 2016. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Dementia-Associated-With-Alzheimer-s-Disease-Pipeline-Review-H2-2016-2088-16704>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.